OPTN vs. CNTX, AMLX, KPTI, PDSB, NVCT, RNAC, VTGN, DMAC, COYA, and MCRB
Should you be buying OptiNose stock or one of its competitors? The main competitors of OptiNose include Context Therapeutics (CNTX), Amylyx Pharmaceuticals (AMLX), Karyopharm Therapeutics (KPTI), PDS Biotechnology (PDSB), Nuvectis Pharma (NVCT), Cartesian Therapeutics (RNAC), Vistagen Therapeutics (VTGN), DiaMedica Therapeutics (DMAC), Coya Therapeutics (COYA), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical preparations" industry.
OptiNose (NASDAQ:OPTN) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, community ranking, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.
85.6% of OptiNose shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 2.2% of OptiNose shares are owned by insiders. Comparatively, 6.7% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
OptiNose presently has a consensus target price of $3.67, indicating a potential upside of 191.01%. Context Therapeutics has a consensus target price of $6.00, indicating a potential upside of 200.00%. Given Context Therapeutics' higher probable upside, analysts plainly believe Context Therapeutics is more favorable than OptiNose.
OptiNose received 231 more outperform votes than Context Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Context Therapeutics an outperform vote while only 63.31% of users gave OptiNose an outperform vote.
OptiNose has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500.
Context Therapeutics has lower revenue, but higher earnings than OptiNose. OptiNose is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, OptiNose had 10 more articles in the media than Context Therapeutics. MarketBeat recorded 20 mentions for OptiNose and 10 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.65 beat OptiNose's score of 0.17 indicating that Context Therapeutics is being referred to more favorably in the news media.
Context Therapeutics has a net margin of 0.00% compared to OptiNose's net margin of -41.55%. OptiNose's return on equity of 0.00% beat Context Therapeutics' return on equity.
Summary
Context Therapeutics beats OptiNose on 9 of the 16 factors compared between the two stocks.
Get OptiNose News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptiNose Competitors List
Related Companies and Tools
